Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial

Jack Cuzick, Ivana Sestak, Sarah E Pinder, Ian O Ellis, Sharon Forsyth, Nigel J Bundred, John F Forbes, Hugh Bishop, Ian S Fentiman, William D George, Jack Cuzick, Ivana Sestak, Sarah E Pinder, Ian O Ellis, Sharon Forsyth, Nigel J Bundred, John F Forbes, Hugh Bishop, Ian S Fentiman, William D George

Abstract

Background: Initial results of the UK/ANZ DCIS (UK, Australia, and New Zealand ductal carcinoma in situ) trial suggested that radiotherapy reduced new breast events of ipsilateral invasive and ductal carcinoma in situ (DCIS) compared with no radiotherapy, but no significant effects were noted with tamoxifen. Here, we report long-term results of this trial.

Methods: Women with completely locally excised DCIS were recruited into a randomised 2×2 factorial trial of radiotherapy, tamoxifen, or both. Randomisation was independently done for each of the two treatments (radiotherapy and tamoxifen), stratified by screening assessment centre, and blocked in groups of four. The recommended dose for radiation was 50 Gy in 25 fractions over 5 weeks (2 Gy per day on weekdays), and tamoxifen was prescribed at a dose of 20 mg daily for 5 years. Elective decision to withhold or provide one of the treatments was permitted. The endpoints of primary interest were invasive ipsilateral new breast events for the radiotherapy comparison and any new breast event, including contralateral disease and DCIS, for tamoxifen. Analysis of each of the two treatment comparisons was restricted to patients who were randomly assigned to that treatment. Analyses were by intention to treat. All trial drugs have been completed and this study is in long-term follow-up. This study is registered, number ISRCTN99513870.

Findings: Between May, 1990, and August, 1998, 1701 women were randomly assigned to radiotherapy and tamoxifen, radiotherapy alone, tamoxifen alone, or to no adjuvant treatment. Seven patients had protocol violations and thus 1694 patients were available for analysis. After a median follow-up of 12·7 years (IQR 10·9-14·7), 376 (163 invasive [122 ipsilateral vs 39 contralateral], 197 DCIS [174 ipsilateral vs 17 contralateral], and 16 of unknown invasiveness or laterality) breast cancers were diagnosed. Radiotherapy reduced the incidence of all new breast events (hazard ratio [HR] 0·41, 95% CI 0·30-0·56; p<0·0001), reducing the incidence of ipsilateral invasive disease (0·32, 0·19-0·56; p<0·0001) as well as ipsilateral DCIS (0·38, 0·22-0·63; p<0·0001), but having no effect on contralateral breast cancer (0·84, 0·45-1·58; p=0·6). Tamoxifen reduced the incidence of all new breast events (HR 0·71, 95% CI 0·58-0·88; p=0·002), reducing recurrent ipsilateral DCIS (0·70, 0·51-0·86; p=0·03) and contralateral tumours (0·44, 0·25-0·77; p=0·005), but having no effect on ipsilateral invasive disease (0·95, 0·66-1·38; p=0·8). No data on adverse events except cause of death were collected for this trial.

Interpretation: This updated analysis confirms the long-term beneficial effect of radiotherapy and reports a benefit for tamoxifen in reducing local and contralateral new breast events for women with DCIS treated by complete local excision.

Funding: Cancer Research UK and the Australian National Health and Medical Research Council.

Copyright © 2011 Elsevier Ltd. All rights reserved.

Figures

Figure 1
Figure 1
Trial profile T=tamoxifen. R=radiotherapy. CT=control group for tamoxifen. CR=control group for radiotherapy.
Figure 2
Figure 2
Kaplan-Meier curve for cumulative incidence and annual hazard plot of all breast events in the tamoxifen comparison
Figure 3
Figure 3
Forest plot for new breast events in the tamoxifen comparison stratified by whether or not patients received radiotherapy HR=hazard ratio. DCIS=ductal carcinoma in situ.
Figure 4
Figure 4
Kaplan-Meier curve for cumulative incidence and annual hazard plot of all breast events in the radiotherapy comparison
Figure 5
Figure 5
Forest plot for new breast events in the radiotherapy comparison stratified by whether or not patients received tamoxifen HR=hazard ratio. DCIS=ductal carcinoma in situ.

References

    1. Mokbel K, Cutuli B. Heterogeneity of ductal carcinoma in situ and its effects on management. Lancet Oncol. 2006;7:756–765.
    1. Tsikitis VL, Chung MA. Biology of ductal carcinoma in situ classification based on biologic potential. Am J Clin Oncol. 2006;29:305–310.
    1. Evans AJ, Pinder SE, Ellis IO. Screen detected ductal carcinoma in situ (DCIS): overdiagnosis or an obligate precursor of invasive disease? J Med Screen. 2001;8:149–151.
    1. Duffy SW, Agbaje O, Tabar L. Overdiagnosis and overtreatment of breast cancer: estimates of overdiagnosis from two trials of mammographic screening for breast cancer. Breast Cancer Res. 2005;7:258–265.
    1. Chakrabarti J, Evans AJ, James J, Ellis IO, Pinder SE, Macmillan RD. Accuracy of mammography in predicting histological extent of ductal carcinoma in situ (DCIS) Eur J Surg Oncol. 2006;32:1089–1092.
    1. Sakorafas GH, Farley DR, Peros G. Recent advances and current controversies in the management of DCIS of the breast. Cancer Treat Rev. 2008;34:483–497.
    1. Fisher B, Dignam J, Wolmark N. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998;16:441–452.
    1. Emdin SO, Granstrand B, Ringberg A. SweDCIS: radiotherapy after sector resection for ductal carcinoma in situ of the breast: results of a randomised trial in a population offered mammography screening. Acta Oncol. 2006;45:536–543.
    1. Julien JP, Bijker N, Fentiman IS. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet. 2000;355:528–533.
    1. Houghton J, George WD, Cuzick J. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362:95–102.
    1. Fisher B, Land S, Mamounas E. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001;28:400–418.
    1. Patani N, Cutuli B, Mokbel K. Current management of DCIS: a review. Breast Cancer Res Treat. 2008;111:1–10.
    1. Cuzick J. Treatment of DCIS—results from clinical trials. Surg Oncol. 2003;12:213–219.
    1. Fisher B, Dignam J, Wolmark N. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353:1993–2000.
    1. Cuzick J. Aromatase inhibitors in prevention—data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study) Recent Results Cancer Res. 2003;163:96–103.
    1. Pinder SE, Duggan C, Ellis IO. A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial. Br J Cancer. 2010;103:94–100.
    1. Bijker N, Meijnen P, Peterse JL. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24:3381–3387.
    1. Holmberg L, Garmo H, Granstrand B. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol. 2008;26:1247–1252.
    1. Anon Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet. 1983;1:257–261.
    1. Anon Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists’ Collaborative Group. N Engl J Med. 1988;319:1681–1692.
    1. Correa C, McGale P, Taylor C. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010;2010:162–177.
    1. Clarke M, Collins R, Darby S. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–2106.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren